| Literature DB >> 23195021 |
Z A Stewart1, T E Collins, A J Schlueter, T I Raife, D G Holanda, R Nair, A I Reed, C P Thomas.
Abstract
ABO-incompatible (ABOI) living donor kidney transplantation has become a well-accepted practice with standard protocols using perioperative antibody-depleting therapies to lower blood group titers to an acceptable threshold for transplantation. However, a subset of patients will experience accelerated antibody-mediated rejection (AMR) after ABOI kidney transplantation and require aggressive intervention to prevent allograft loss. Here in we report the successful use of terminal complement inhibition with eculizumab to rescue an ABOI kidney allograft with accelerated AMR refractory to salvage splenectomy and daily plasmapheresis. This case emphasizes the fact that, despite close postoperative surveillance and aggressive intervention, graft loss from accelerated AMR after ABOI kidney transplantation remains a very real risk. Eculizumab may offer a graft-saving therapeutic option for isolated cases of severe AMR after ABOI kidney transplantation refractory to standard treatment.Entities:
Mesh：
Substances：
Year: 2012 PMID： 23195021 DOI： 10.1016/j.transproceed.2012.03.053
Source DB: PubMed Journal: Transplant Proc ISSN： 0041-1345 Impact factor: 1.066